%0 Journal Article
%T From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma.
%A Zhao J
%A Zheng M
%A Ma L
%A Guan T
%A Su L
%J Heliyon
%V 10
%N 9
%D 2024 May 15
%M 38699030
%F 3.776
%R 10.1016/j.heliyon.2024.e29997
%X Multiple myeloma (MM), marked by abnormal proliferation of plasma cells and production of monoclonal immunoglobulin heavy or light chains in the majority of patients, has traditionally been associated with poor survival, despite improvements achieved in median survival in all age groups since the introduction of novel agents. Survival has significantly improved with the development of new drugs and new treatment options, such as chimeric antigen receptor T-cell therapy (CAR-T), which have shown promise and given new hope in MM therapy. CARs are now classified as first-, second-, and third-generation CARs based on the number of monovalent to trivalent co-stimulatory molecules incorporated into their design. The scope of this review was relatively narrow because it was mainly about a comparison of the literature on the clinical application of CAR-T therapy in MM. Thus, our goal is to provide an overview of the new advances of CAR-T cells in the cure of MM, so in this review we looked at the progress of the clinical use of CAR-T cells in MM to try to provide a reference for their clinical use when managing MM.